# Diamond Capital Management

> Diamond Capital Management is a VC fund in Pewaukee backing Biotechnology and Medical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Pewaukee, United States
- Total investments: 2
- Last investment: Mar 2004
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.diamondcapitalmgmt.com/

Diamond Capital Management is a VC fund in Pewaukee focused on Biotechnology and Medical. Diamond Capital Management is dedicated to offering clients well managed alternative investment products that offer consistent returns and protection of principal achieved through the proper application of money management and continuous evaluation of risk exposure. The principals at Diamond Capital have a solid understanding of the markets and theinstruments utilized in the strategies. Past experience has demonstrated that using modifications of tried and true concepts such as proper portfolio diversification, diligent adaptation to market volatility, dollar-cost-averaging with judicious profit taking throughout the investment term, among others, hold the most promise.Our success is measured against other investment benchmarks, as well as peer group and related industry benchmarks. While short-term performance is always difficult to predict, our long-term goal is to provide consistently attractive returns, within reasonable risk parameters.In doing so, we at Diamond Capital take personal pride in managing accounts with our clients' best interest in mind.Diamond Capital Management, LLC, ("DCM") is registered with the Commodity Futures Trading Commission ("CFTC") as a Commodity Trading Advisor ("CTA") and is a member of the National Futures Association ("NFA").We invite you to investigate Diamond's strategies further and discover a non-correlated alternative investment products to compliment your long term investment goals. To learn more about Diamond Capital and the potential value DCM can add to your overall portfolio, please explore our site, or contact us directly.Past performance is not necessarily a representation of future results. Alternative investments such as managed futures investments are speculative, involve substantial risk, and are not suitable for all investors.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Neuroscience | 1 | 50% |
| Therapeutics | 1 | 50% |

7 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TransMolecular | TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technologyplatforms to enrich its product discovery and development pipeline.Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms.The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama.TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively. | $33.2M | Series C | Mar 01, 2004 |  |
| NeurogesX | NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's leadproduct candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic pain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California. | $35M | Series C | Feb 24, 2004 |  |

2 of 2 investments shown.

## Co-investors
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- Cogene Ventures — VC Fund, 1 deal together
- Dow Pension Funds — VC Fund, 1 deal together
- [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Diamond Capital Management invest in?

Diamond Capital Management invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Diamond Capital Management last invest?

The most recent investment recorded for Diamond Capital Management closed in Mar 2004. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co